Article Text
Abstract
A 25-year-old man who received alemtuzumab as induction therapy for a multivisceral transplant experienced delayed onset of warm autoimmune haemolytic anaemia and neutropaenia. Serological testing and bone marrow biopsy excluded alternative causes. Haemolysis was refractory to standard therapies including corticosteroids, intravenous immunoglobulin and rituximab. The patient was successfully treated with bortezomib, a proteasome inhibitor, and has remained well as an outpatient without evidence of ongoing haemolysis.
- transplantation
- haematology (drugs and medicines)
- GI bleeding
Statistics from Altmetric.com
Footnotes
Contributors DW was responsible for drafting the manuscript, literature review, obtaining patient consent and reviewing the manuscript. WT, AB and LS were responsible for planning and conception of the manuscript, as well as critical review.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.